Deutsche Bank
ACRS icon

Deutsche Bank’s Aclaris Therapeutics ACRS Stock Holding History

Deutsche Bank’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.74M Buy
997,850
+10,499
+1% +$35.4K ﹤0.01% 1449
2025
Q4 		$2.97M Buy
987,351
+64,038
+7% +$162K ﹤0.01% 1567
2025
Q3 		$1.75M Sell
923,313
-83,236
-8% -$145K ﹤0.01% 1860
2025
Q2 		$1.43M Buy
1,006,549
+83,236
+9% +$113K ﹤0.01% 1894
2025
Q1 		$1.41M Hold
923,313
– – ﹤0.01% 1970
2024
Q4 		$2.29M Hold
923,313
– – ﹤0.01% 1762
2024
Q3 		$1.06M Hold
923,313
– – ﹤0.01% 2082
2024
Q2 		$1.02M Sell
923,313
-33,708
-4% -$39.6K ﹤0.01% 1978
2024
Q1 		$1.19M Buy
957,021
+22,975
+2% +$27.4K ﹤0.01% 1935
2023
Q4 		$981K Buy
934,046
+779,737
+505% +$2.38M ﹤0.01% 2040
2023
Q3 		$1.06M Sell
154,309
-932,311
-86% -$7.97M ﹤0.01% 1685
2023
Q2 		$11.3M Sell
1,086,620
-15,577
-1% -$141K 0.01% 946
2023
Q1 		$8.92M Sell
1,102,197
-75,396
-6% -$957K 0.01% 1011
2022
Q4 		$18.5M Buy
1,177,593
+8,696
+0.7% +$140K 0.01% 784
2022
Q3 		$18.4M Sell
1,168,897
-5,804
-0.5% -$91.4K 0.01% 780
2022
Q2 		$16.4M Sell
1,174,701
-292,402
-20% -$4.1M 0.01% 835
2022
Q1 		$25.3M Buy
1,467,103
+1,213,032
+477% +$16.5M 0.01% 774
2021
Q4 		$3.69M Sell
254,071
-68,368
-21% -$1.04M ﹤0.01% 1617
2021
Q3 		$5.8M Sell
322,439
-11,795
-4% -$189K ﹤0.01% 1421
2021
Q2 		$5.87M Buy
334,234
+75,523
+29% +$1.72M ﹤0.01% 1430
2021
Q1 		$6.52M Buy
258,711
+193,083
+294% +$3.78M ﹤0.01% 1410
2020
Q4 		$425K Hold
65,628
– – ﹤0.01% 3013
2020
Q3 		$169K Hold
65,628
– – ﹤0.01% 3305
2020
Q2 		$106K Buy
65,628
+26,605
+68% +$35.6K ﹤0.01% 3403
2020
Q1 		$41K Sell
39,023
-628
-2% -$855 ﹤0.01% 3636
2019
Q4 		$73K Buy
39,651
+30,372
+327% +$50.3K ﹤0.01% 3740
2019
Q3 		$9K Sell
9,279
-444,690
-98% -$631K ﹤0.01% 4523
2019
Q2 		$992K Buy
453,969
+366,558
+419% +$2M ﹤0.01% 2844
2019
Q1 		$522K Buy
87,411
+27,553
+46% +$183K ﹤0.01% 3420
2018
Q4 		$442K Sell
59,858
-263,723
-82% -$2.72M ﹤0.01% 3429
2018
Q3 		$4.7M Buy
323,581
+94,306
+41% +$1.62M ﹤0.01% 2238
2018
Q2 		$4.58M Buy
229,275
+131,874
+135% +$2.44M ﹤0.01% 2363
2018
Q1 		$1.71M Sell
97,401
-82,221
-46% -$1.74M ﹤0.01% 2977
2017
Q4 		$4.43M Buy
179,622
+40,784
+29% +$993K ﹤0.01% 2118
2017
Q3 		$3.58M Buy
138,838
+19,309
+16% +$518K ﹤0.01% 2127
2017
Q2 		$3.24M Buy
119,529
+29,368
+33% +$798K ﹤0.01% 2225
2017
Q1 		$2.69M Sell
90,161
-20,122
-18% -$580K ﹤0.01% 2064
2016
Q4 		$2.99M Buy
110,283
+58,688
+114% +$1.5M ﹤0.01% 2001
2016
Q3 		$1.32M Buy
51,595
+15,218
+42% +$323K ﹤0.01% 2641
2016
Q2 		$671K Buy
36,377
+35,513
+4,110% +$704K ﹤0.01% 3119
2016
Q1 		$16K Sell
864
-582
-40% -$11.1K ﹤0.01% 4693
2015
Q4 		$38K Buy
+1,446
New +$28.2K ﹤0.01% 4523

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank's ACRS Position: Q1 2026 in Review

Deutsche Bank increased its Aclaris Therapeutics (ACRS) stake by 1.1% in Q1 2026, buying an estimated $35.4K and bringing the position to 997,850 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1449.

Deutsche Bank first reported a position in ACRS in Q4 2015 and has held it in 42 quarters since. The position peaked at $25.3M in Q1 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Deutsche Bank held 997,850 shares of Aclaris Therapeutics worth $3.74M as of Q1 2026.
  • Deutsche Bank bought 10,499 Aclaris Therapeutics shares in Q1 2026, an estimated $35.4K.
  • Aclaris Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1449 holding.
  • Deutsche Bank first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • Deutsche Bank's Aclaris Therapeutics position peaked at $25.3M in Q1 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.